ASCO: AstraZeneca, Daiichi's Enhertu delivers 'very compelling' pan-tumor activity, experts say
Fierce Pharma
JUNE 4, 2023
AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. | AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. Now, the companies are positioning the HER2 antibody-drug conjugate for expansion into other tumor types with data that researchers view as very compelling.
Let's personalize your content